Celcuity Inc.

For the period ended Sep 30, 2026. Filed Sep 30, 2026.

About this filing

A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.

Sep 30, 2026 · Filed Sep 30, 2026

Use the contents to explore the available documents and sections.

CELC$66.79+4.3%Stored close · as of Nov 6, 2026

See the whole filing, with its images and exhibits

EX-99.1 · Indication Statement

Indication Statement

REVTORPYK (gedatolisib) is a kinase inhibitor indicated in combination with fulvestrant, with or without palbociclib, for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.